Grant Details

General Overview

Grant Information

Grant name: Development of Medications to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)

Funding organization: National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Total funding amount: Up to $3 million per year for direct costs

Duration: Maximum project period of 5 years

Primary objective: To support research for the discovery and development of medications to prevent and treat SUDs and overdose

Funding source: Federal government

Funding type: Cooperative agreement

Significance: Addresses the urgent need for effective medications to combat the substance use crisis

Grant frequency: Recurring

Organizational Aspects

Eligible Organization Types

Higher Education Institutions

Public/State Controlled Institutions of Higher Education

Private Institutions of Higher Education

Nonprofits (with and without 501(c)(3) status)

For-Profit Organizations (including Small Businesses)

Local, State, County, City or Township Governments

Indian/Native American Tribal Governments (both Federally Recognized and Other)

Federal Government Agencies

U.S. Territories or Possessions

Other entities including Independent School Districts, Public Housing Authorities, Faith-based Organizations, and Foreign Organizations

Scope and Focus

Research Focus

Preclinical and clinical research studies aimed at advancing medications for SUD and overdose

Focus on new chemical entities, biologics, and repurposed medications

Specific interest in compounds that prevent initiation and progression of SUDs, improve treatment adherence, and reduce overdose risks

Technical Details

Technical Expertise Requirements

Investigators must have the skills and resources necessary to conduct the proposed research

Applications must include a detailed research strategy and milestones for both UG3 and UH3 phases

Financial Structure

Budget and Funding

Application budgets are limited to $3 million per year for direct costs

No cost-sharing is required

Timeline and Implementation

Key Dates

Open Date: March 10, 2025

Application Due Date: August 11, 2025

Expiration Date: August 12, 2025

Compliance and Requirements

Regulatory Compliance

Applicants must comply with NIH Grants Policy Statement and federal regulations

Required registrations include System for Award Management (SAM), eRA Commons, and Grants.gov

Application Process

Submission Requirements

Applications must be submitted electronically via Grants.gov or NIH ASSIST

Compliance with application instructions is strictly enforced

Grant Details

substance use disorder medications clinical trial healthcare research drug overdose biologics pharmaceuticals public health
Development of Medications to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
PAR-25-329
NIH Grants
EDU NGO ENTERPRISE PUBLIC RESEARCH OTHER
US
HEALTHCARE OTHER
DEVELOPMENT OTHER
0-10 11-50 51-250 251-500 500+
SDG3
FUNDING RESEARCH_DEVELOPMENT
None
3000000.00
None
3000000.00
USD
None
Aug. 11, 2025, 10 p.m.
March 2025 - August 2025